mitoxantrone has been researched along with Glial Cell Tumors in 12 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, novel efficient pH-responsive boron phenylalanine (BPA) targeted nanoparticles (NPs) based on ionic liquid modified chitosan have been introduced for selective mitoxantrone (MTO) delivery to the U87MG glioma cells." | 8.02 | Boron phenyl alanine targeted ionic liquid decorated chitosan nanoparticles for mitoxantrone delivery to glioma cell line. ( Dousti, F; Hassanzadeh, F; Kasesaz, Y; Mirian, M; Rostami, M; Soleimanbeigi, M; Varshosaz, J, 2021) |
| "Mitoxantrone (MTZ) has potent in vitro activity against malignant glioma cell lines, but it cannot be used effectively as a systemic agent for the treatment of brain tumors because of its poor central nervous system penetration." | 7.73 | Treatment of malignant gliomas with mitoxantrone-loaded poly (lactide-co-glycolide) microspheres. ( Bozdag, S; Capan, Y; Cetin, M; Dalkara, T; Söylemezoglu, F; Vural, I; Yemisci, M, 2006) |
| "We undertook a phase I-II trail of loco-regional mitoxantrone in 12 patients affected by malignant gliomas." | 7.69 | Interstitial chemotherapy with mitoxantrone in recurrent malignant glioma: preliminary data. ( Boiardi, A; Broggi, G; Pozzi, A; Salmaggi, A; Silvani, A, 1996) |
| "Mitoxantrone is a highly cytotoxic antineoplastic drug, however, its poor penetration of the blood-brain barrier has limited its role in the treatment of brain cancers." | 5.43 | Safety, feasibility, and optimization of intra-arterial mitoxantrone delivery to gliomas. ( Bigio, IJ; Bruce, JN; Cooke, J; Ellis, JA; Emala, CW; Joshi, S; Singh-Moon, RP; Wang, M, 2016) |
| " In this study, novel efficient pH-responsive boron phenylalanine (BPA) targeted nanoparticles (NPs) based on ionic liquid modified chitosan have been introduced for selective mitoxantrone (MTO) delivery to the U87MG glioma cells." | 4.02 | Boron phenyl alanine targeted ionic liquid decorated chitosan nanoparticles for mitoxantrone delivery to glioma cell line. ( Dousti, F; Hassanzadeh, F; Kasesaz, Y; Mirian, M; Rostami, M; Soleimanbeigi, M; Varshosaz, J, 2021) |
| " We then applied the same scheme to evaluate IA mitoxantrone delivery to glioma-bearing rats." | 3.80 | Spatial mapping of drug delivery to brain tissue using hyperspectral spatial frequency-domain imaging. ( Bigio, IJ; Joshi, S; Roblyer, DM; Singh-Moon, RP, 2014) |
| "Mitoxantrone (MTZ) has potent in vitro activity against malignant glioma cell lines, but it cannot be used effectively as a systemic agent for the treatment of brain tumors because of its poor central nervous system penetration." | 3.73 | Treatment of malignant gliomas with mitoxantrone-loaded poly (lactide-co-glycolide) microspheres. ( Bozdag, S; Capan, Y; Cetin, M; Dalkara, T; Söylemezoglu, F; Vural, I; Yemisci, M, 2006) |
| "The present study was designed to test the efficacy of intratumoral biopolymer-mediated mitoxantrone chemotherapy in the rat brain 9L glioma model." | 3.72 | Intralesional mitoxantrone biopolymer-mediated chemotherapy prolongs survival in rats with experimental brain tumors. ( Bellinzona, M; Hussein, S; Roser, F; Saini, M; Samii, M, 2004) |
| "We undertook a phase I-II trail of loco-regional mitoxantrone in 12 patients affected by malignant gliomas." | 3.69 | Interstitial chemotherapy with mitoxantrone in recurrent malignant glioma: preliminary data. ( Boiardi, A; Broggi, G; Pozzi, A; Salmaggi, A; Silvani, A, 1996) |
| "Mitoxantrone is a highly cytotoxic antineoplastic drug, however, its poor penetration of the blood-brain barrier has limited its role in the treatment of brain cancers." | 1.43 | Safety, feasibility, and optimization of intra-arterial mitoxantrone delivery to gliomas. ( Bigio, IJ; Bruce, JN; Cooke, J; Ellis, JA; Emala, CW; Joshi, S; Singh-Moon, RP; Wang, M, 2016) |
| "Temozolomide, the standard treatment of gliomas, although not an ABCG2 substrate, increases the SP in glioma cells, especially in cells missing PTEN." | 1.35 | PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. ( Bleau, AM; Brennan, CW; Fomchenko, EI; Hambardzumyan, D; Holland, EC; Huse, JT; Ozawa, T, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kokoshka, JM | 1 |
| Ireland, CM | 1 |
| Barrows, LR | 1 |
| Dousti, F | 1 |
| Soleimanbeigi, M | 1 |
| Mirian, M | 1 |
| Varshosaz, J | 1 |
| Hassanzadeh, F | 1 |
| Kasesaz, Y | 1 |
| Rostami, M | 1 |
| Singh-Moon, RP | 2 |
| Roblyer, DM | 1 |
| Bigio, IJ | 2 |
| Joshi, S | 2 |
| Ellis, JA | 1 |
| Cooke, J | 1 |
| Wang, M | 1 |
| Bruce, JN | 1 |
| Emala, CW | 1 |
| Bleau, AM | 1 |
| Hambardzumyan, D | 1 |
| Ozawa, T | 1 |
| Fomchenko, EI | 1 |
| Huse, JT | 1 |
| Brennan, CW | 1 |
| Holland, EC | 1 |
| Jin, Y | 1 |
| Bin, ZQ | 1 |
| Qiang, H | 1 |
| Liang, C | 1 |
| Hua, C | 1 |
| Jun, D | 1 |
| Dong, WA | 1 |
| Qing, L | 1 |
| Martin, V | 1 |
| Xu, J | 1 |
| Pabbisetty, SK | 1 |
| Alonso, MM | 1 |
| Liu, D | 1 |
| Lee, OH | 1 |
| Gumin, J | 1 |
| Bhat, KP | 1 |
| Colman, H | 1 |
| Lang, FF | 1 |
| Fueyo, J | 1 |
| Gomez-Manzano, C | 1 |
| Saini, M | 1 |
| Roser, F | 1 |
| Hussein, S | 1 |
| Samii, M | 1 |
| Bellinzona, M | 1 |
| Yemisci, M | 1 |
| Bozdag, S | 1 |
| Cetin, M | 1 |
| Söylemezoglu, F | 1 |
| Capan, Y | 1 |
| Dalkara, T | 1 |
| Vural, I | 1 |
| Boiardi, A | 2 |
| Salmaggi, A | 2 |
| Pozzi, A | 1 |
| Broggi, G | 2 |
| Silvani, A | 2 |
| Eoli, M | 1 |
| Zappacosta, B | 1 |
| Fariselli, L | 1 |
| Milanesi, I | 1 |
| Nikkhah, G | 1 |
| Tonn, JC | 1 |
| Hoffmann, O | 1 |
| Kraemer, HP | 1 |
| Darling, JL | 1 |
| Schachenmayr, W | 1 |
| Schönmayr, R | 1 |
1 trial available for mitoxantrone and Glial Cell Tumors
| Article | Year |
|---|---|
Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Female; Glioma; Humans; Magnetic Re | 2001 |
11 other studies available for mitoxantrone and Glial Cell Tumors
| Article | Year |
|---|---|
Cell-based screen for identification of inhibitors of tubulin polymerization.
Topics: Animals; Brain Neoplasms; Bucladesine; Cell Differentiation; Drug Screening Assays, Antitumor; Forma | 1996 |
Boron phenyl alanine targeted ionic liquid decorated chitosan nanoparticles for mitoxantrone delivery to glioma cell line.
Topics: Antineoplastic Agents; Boron; Cell Line, Tumor; Chitosan; Glioma; Humans; Microscopy, Electron, Tran | 2021 |
Spatial mapping of drug delivery to brain tissue using hyperspectral spatial frequency-domain imaging.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Glioma; Image Processing, Computer-Assisted; | 2014 |
Safety, feasibility, and optimization of intra-arterial mitoxantrone delivery to gliomas.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Cell Line, Tumor; Dose-Response Relationship | 2016 |
PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, | 2009 |
ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; | 2009 |
Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette | 2009 |
Intralesional mitoxantrone biopolymer-mediated chemotherapy prolongs survival in rats with experimental brain tumors.
Topics: Animals; Antineoplastic Agents; Biopolymers; Brain Neoplasms; Delayed-Action Preparations; Disease M | 2004 |
Treatment of malignant gliomas with mitoxantrone-loaded poly (lactide-co-glycolide) microspheres.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Drug | 2006 |
Interstitial chemotherapy with mitoxantrone in recurrent malignant glioma: preliminary data.
Topics: Adult; Antineoplastic Agents; Catheters, Indwelling; Chemotherapy, Cancer, Regional Perfusion; Elect | 1996 |
The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part II: Evaluation of patient- and drug-specific variables.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Survival; Colony-Forming Units Assay; Color | 1992 |